Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Ionis, AstraZeneca move antisense drug for cardiovascular disease into preclinical studies

Dec. 22, 2016

Merck & Co. patents sGC activators

Dec. 19, 2016

BlueRock obtains sublicense to cardiac stem cell technologies from VistaGen

Dec. 16, 2016

Merck & Co. discovers soluble guanylate cyclase activators

Dec. 15, 2016

Novel model reveals roles of Iroquois homeobox proteins in left ventricular noncompaction

Dec. 13, 2016

Amgen patents appelin receptor agonists

Dec. 13, 2016

3D microtissue engineering used to generate hypertrophic cardiomyopathy cardiomyocytes

Dec. 12, 2016

GALACTIC-HF phase III trial of omecamtiv mecarbil begins

Dec. 2, 2016

Medshine Discovery develops PDE2A inhibitors and TNF-alpha production inhibitors

Dec. 2, 2016

Chugai files for approval of Actemra for additional indication in Japan

Dec. 1, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....